
Astria Therapeutics (ATXS) Stock Forecast & Price Target
Astria Therapeutics (ATXS) Analyst Ratings
Bulls say
The positive outlook on Astria Therapeutics's stock is supported by the anticipated momentum in 2025, driven by clinical updates and promising data from its key programs, STAR-0215 and STAR-0310, which address significant medical needs in hereditary angioedema (HAE) and atopic dermatitis. The impressive results from the ALPHA-STAR Phase 1b/2 clinical trial, which demonstrated a 90-95% reduction in monthly attack rates for HAE patients, along with favorable pharmacokinetics and pharmacodynamics, bolster confidence in the therapeutic potential of navenibart as a differentiated prophylactic treatment. Additionally, the preclinical data for STAR-0310 reveal a substantial enhancement in binding affinity and reduced cytotoxicity compared to existing therapies, indicating a strong advantage that may translate into effective treatment options for patients with atopic dermatitis.
Bears say
Astria Therapeutics faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential for failed clinical trials and inadequate funding, which could hinder the progression of its drug candidates. The company reported fourth-quarter and full-year financial results that indicate higher-than-expected losses, with earnings per share (EPS) at ($0.44) for 4Q24 and ($1.68) for the full year, slightly better but still below estimates. Additionally, the competitive landscape poses challenges, particularly in achieving commercial success against established products like Dupixent, highlighting an uncertain efficacy/safety profile that could further impact investor confidence and stock performance.
This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Astria Therapeutics (ATXS) Analyst Forecast & Price Prediction
Start investing in Astria Therapeutics (ATXS)
Order type
Buy in
Order amount
Est. shares
0 shares